Molecular Bilayer Structure (e.g., Vesicle, Liposome) Patents (Class 424/1.21)
-
Publication number: 20120309628Abstract: The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.Type: ApplicationFiled: August 14, 2012Publication date: December 6, 2012Applicant: Children's Hospital and Research Center at OaklandInventors: Robert O. Ryan, Michael N. Oda
-
Publication number: 20120282172Abstract: The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target organ, like, for example, tumor cells and/or vascular cells of tumor blood vessels. Moreover, this invention provides a method where, upon internalization of the previous-mentioned system by the target cells, triggered release at a high rate of the associated agent takes place, permitting efficient intracellular delivery and, thus, increased concentration of the transported cargo at the target site. Overall, this invention provides a method for the diagnosis, prevention and treatment of human diseases and disorders.Type: ApplicationFiled: May 9, 2012Publication date: November 8, 2012Applicants: Centro de Neurociencias e Biologia Celular, Universidade de CoimbraInventors: João Nuno Sereno de Almeida Moreira, Vera Lúcia Dantas Nunes Caldeira de Moura, Sérgio Paulo de Magalhães Simões, Maria da Conceição Monteiro Pedroso de Lima
-
Patent number: 8277823Abstract: The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable.Type: GrantFiled: May 21, 2010Date of Patent: October 2, 2012Assignee: Statens Serum InstitutInventors: Jesper Davidsen, Peter Andersen, Ida Rosenkrands
-
Patent number: 8236770Abstract: The invention relates to amphoteric liposomal formulations which are provided with great serum stability and are suitable for the intracellular delivery of oligonucleotides.Type: GrantFiled: March 29, 2005Date of Patent: August 7, 2012Assignee: Marina Biotech, Inc.Inventors: Gerold Endert, Yvonne Kerwitz, Monika Fellermeier
-
Publication number: 20120164065Abstract: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.Type: ApplicationFiled: January 11, 2012Publication date: June 28, 2012Inventors: Anthony Manganaro, Karen Rockwell
-
Publication number: 20120128582Abstract: A method for the treatment of atherosclerosis. The method includes the administration of a 32P-labeled agent as a beta emitter, such as 32P-labeled ATP or other 32P-labeled adenine nucleotides, whereby the 32P-labeled agent seeks and then permeates the atherosclerotic plaque en bloc without prior degradation. The accumulation of the 32P-labeled agent in the atherosclerotic plaque is achieved at time points whereby the 32P-labeled agent is cleared from the blood. Thus, radionuclide-labeled adenine nucleotides accumulate with high specificity in atherosclerotic lesions and in the heart. The beta particles (electrons) emitted by the 32P-label have a maximal path distance of about 0.5 cm and their energy preferentially destroy cells present in the atherosclerotic plaque without affecting vessel integrity or inducing arterial thrombosis.Type: ApplicationFiled: July 18, 2011Publication date: May 24, 2012Inventor: Eliezer Rapaport
-
Publication number: 20120107232Abstract: A kit for preparing a radiolabeled liposome is provided, the kit including a liposome suspension and a radionuclide, wherein the liposome suspension includes a conjugate with a structure of [chelator-hydrophilic polymer-lipid]. A method for preparing a radiolabeled liposome using the kit is also disclosed herein, thereby the radiolabeled liposome being produced with the conjugate connected to the surface therein. The advantages of the present disclose such as simple, convenient and without purifying for the produced radiolabeled liposome are thus achieved. Further, the produced radiolabeled liposome has a high specific activity and a high sensitivity and suits for the clinical use.Type: ApplicationFiled: June 27, 2011Publication date: May 3, 2012Applicant: Institute of Nuclear Energy Research Atomic Energy Council, Executive YuanInventors: WEI-CHUAN HSU, Te-Wei Lee, Shu-Pei Chiu, Yi-Ting Tsai, Gann Ting
-
Publication number: 20120082616Abstract: The present invention provides targeted delivery compositions and their methods of use in treating and diagnosing a disease state in a subject.Type: ApplicationFiled: September 23, 2011Publication date: April 5, 2012Applicant: Mallinckrodt LLCInventors: Bobby N. Trawick, Todd A. Osiek, James R. Wheatley, JR.
-
Patent number: 8148130Abstract: T4 bacteriophages are bound to substrates such as liposomes using a binder.Type: GrantFiled: February 29, 2008Date of Patent: April 3, 2012Assignee: The Catholic University of AmericaInventors: Carl R. Alving, Venigalla Rao
-
Patent number: 8137540Abstract: Disclosed are improved methods and apparatus for radiolabeling, particularly methods and apparatus for large scale in-line radiolabeling of products, such as proteins and antibodies.Type: GrantFiled: August 20, 2009Date of Patent: March 20, 2012Assignee: Peregrine Pharmaceuticals, Inc.Inventors: Raimo Pellikka, Steven W. King, Peter Bläuenstein, Pius A. Schubiger
-
Patent number: 8119101Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions.Type: GrantFiled: May 28, 2010Date of Patent: February 21, 2012Assignees: The Ohio State University, Immunomedics, Inc.Inventors: John C. Byrd, David M. Goldenberg, Hans J. Hansen
-
Publication number: 20120041357Abstract: Disclosed are methods and compositions for the controlled release of a drug or agent from a liposome using light or radiation. Also disclosed are compositions comprising liposomes having a lipid layer, wherein the liposomes contain an agent, an enzyme capable of releasing the agent from the liposome, and an enzyme activator sequestered by a molecular cage. In another aspect, methods of delivering an agent to a target in a subject are disclosed.Type: ApplicationFiled: March 31, 2010Publication date: February 16, 2012Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSASInventors: Daniel Fologea, Greg Salamo, Ralph Henry, Michael J. Borrelli, Peter M. Corry
-
Publication number: 20120034157Abstract: The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.Type: ApplicationFiled: August 3, 2010Publication date: February 9, 2012Inventors: Roderick A. Hyde, Muriel Y. Ishikawa, Wayne A. Kindsvogel, Gary L. McKnight, Elizabeth A. Sweeney, Lowell L. Wood, JR.
-
Publication number: 20120020878Abstract: The present invention comprises a method for delivering pharmaceutical and/or imaging agents within and/or through the dermal, mucosal and other cellular membranes, and across the blood-brain barrier, utilizing a fusogenic protein. The fusogenic protein is associated with a phospholipid membrane, such as a liposome. The liposome may include dioleoylphosphatidylserine, a negatively charged long-chain lipid. Alternatively, the liposome is comprised of a mixture of negatively charged long-chain lipids, neutral long-chain lipids, and neutral short-chain lipids. Preferred fusogenic proteins include saposin C and other proteins, polypeptides and peptide analogs derived from saposin C. The active agent contained within the liposome may comprise biomolecules and/or organic molecules. This technology can be used for both cosmetic and medicinal applications in which the objective is delivery of the active agent within and/or beneath biological membranes or across the blood-brain barrier and neuronal membranes.Type: ApplicationFiled: November 7, 2008Publication date: January 26, 2012Applicant: CHILDREN'S HOSPITAL MEDICAL CENTERInventor: Xiaoyang Qi
-
Publication number: 20120021020Abstract: The present invention provides branched amphipathic peptides and vesicles formed thereof. The peptides comprise a polar/positively charged C-terminal segment, a branch point, and two hydrophobic N -terminal segments extending from the branch point. The vesicles are formed using a plurality of first and second peptides, wherein the first peptide has a different chain length from the second peptide. When a plurality of the first and second peptides are mixed together, they self-assemble to form small spheres defined by a membrane consisting of an interlocking peptide network bilayer and having a liquid-receiving interior space (i.e., hollow core). In the bi-layer, the respective hydrophobic segments of the peptides form beta-sheet structures having a hydrogen bond-stabilized, anti-parallel orientation in which the opposed sequences interlock to form a zipper-like structure in three dimensions. Thus, the peptide assembly (i.e.Type: ApplicationFiled: March 26, 2010Publication date: January 26, 2012Applicant: KANSAS STATE UNIVERSITY RESEARCH FOUNDATIONInventors: John M. Tomich, Takeo Iwamoto, Yasuaki Hiromasa, Sushanth Gudlur
-
Publication number: 20110311442Abstract: A lipid vesicle comprising a phospholipid which is a stable vesicle former and at least one unstable vesicle forming member, wherein the unstable vesicle forming member is selected from the group consisting of a polar lipid which is not a stable vesicle former, a PEG, a raft former and a fusion protein is provided. The vesicle can further comprise a biomolecule, such as for example ATP. Methods of using the vesicle for delivery of biomolecules are also provided.Type: ApplicationFiled: June 17, 2011Publication date: December 22, 2011Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: William D. Ehringer, Sufan Chien
-
Patent number: 8067380Abstract: A delivery system is provided. The delivery system includes a carrier or an active compound and a glutathione or a glutathione derivative grafted thereon. The invention also provides a compound including a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or a polyethylene glycol derivative bonded thereto, and a glutathione (GSH) or a glutathione derivative bonded to the polyethylene glycol or the polyethylene glycol derivative.Type: GrantFiled: October 2, 2008Date of Patent: November 29, 2011Assignee: Industrial Technology Research InstituteInventors: Ae-June Wang, Chi-Heng Jian, Shyh-Dar Li, Yi-Fong Lin, Shin-Jr Liu
-
Patent number: 8058256Abstract: A carrier for delivering small interfering RNA (siRNA) into cells includes a cholesterol residue covalently bonded to oligoarginine. Mixing the siRNA with the carrier produces a complex-containing composition. Contacting a cell with the complex-containing composition results in delivery of the siRNA into the cell. Delivery of an siRNA targeted to vascular endothelial growth factor is a treatment for cancer. Methods of making the carrier and complex are also disclosed.Type: GrantFiled: January 21, 2010Date of Patent: November 15, 2011Assignee: University of Utah Research FoundationInventors: Won Jong Kim, Sung Wan Kim
-
Publication number: 20110274617Abstract: A nanoconjugate is formed from a self-assembled unilamellar vesicle (ULV), at least one contrast agent which may be a MRI contrast agent, a radioisotope or a fluorophore, and at least one antibody, which may be an IgG or an antibody fragment such as a single-domain antibody. The nanoconjugate be targetted with the antibody to receptors specific to certain disease states, and thus be used in diagnostic and imaging methods using the properties o contrast agent.Type: ApplicationFiled: November 26, 2009Publication date: November 10, 2011Applicant: NATIONAL RESEARCH COUNCIL OF CANADAInventors: Abedelnasser Abulrob, Danica Stanimirovic, Umar Iqbal, Mu-Ping Nieh, John Katsaras
-
Publication number: 20110268655Abstract: An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including ?v?1, ?v?3 ?v?5, ?v?6, or ?v?8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab? fragment, a scFv, or the like. Binding of the immunoliposome to ?v-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.Type: ApplicationFiled: May 11, 2011Publication date: November 3, 2011Inventors: Joshua Goldstein, Allen Magill, Deepak Saini, Linda A. Snyder, Raymond Sweet, Steve P. Weng
-
Publication number: 20110270151Abstract: Disclosed are compositions and methods for targeted drug delivery using image-guided energy deposition to help localize active compounds to particular sites within the body of an animal. Also provided are compounds and formulations thereof for use in the targeted administration of therapeutically, prophylactically, and/or diagnostically effective amounts of such agents to a population of cells or tissues of a mammal in need thereof.Type: ApplicationFiled: September 8, 2009Publication date: November 3, 2011Applicant: The Methodist Hospital Research InstituteInventor: King Chuen Li
-
Patent number: 8034385Abstract: The invention relates to a cosmetic based on various natural raw materials, which can be used to counter ageing processes of the human skin. The inventive cosmetic contains 0.1-5% by weight of an extract from a mixture of fig leaves and fruits, 0.1-3% by weight of an extract from pomegranate fruits, 0.001-0.5% by weight of a ground dry mixture of rosemary stems and leaves, 0.01-3% by weight of liposomes containing an extract from peeled musk melons, 0.1-5% by weight of liposomes containing a plankton extract containing the photolyase enzyme, 0.1-5% by weight of liposomes containing 0.1 to 0.5% by weight, in relation to the liposome weight, of a micrococcus lysate containing the UV-endonuclease enzyme; and up to 100% by weight, other active substances, carrier substances, adjuvants or mixtures thereof.Type: GrantFiled: June 23, 2003Date of Patent: October 11, 2011Assignee: Coty B.V.Inventors: Karin Golz-Berner, Leonhard Zastrow
-
Patent number: 8029795Abstract: A targeted iron chelator delivery system that comprises an iron chelator, a targeting agent and a lipid carrier, e.g., a liposome, is provided. The iron chelator delivery system may be used to remove excess iron from specific organs such as, for example, heart and liver tissue. Methods for preparing and administering the targeted iron chelator delivery system are also provided. The iron chelator delivery system may be administered during a blood transfusion to prevent iron overload.Type: GrantFiled: December 14, 2004Date of Patent: October 4, 2011Assignee: Gwathmey, Inc.Inventor: Judith K. Gwathmey
-
Publication number: 20110223103Abstract: The present invention provides multiple modalities for detecting LOX-1. More particularly, an imaging composition is provided that allows for the in vivo imaging of atherosclerotic plaque.Type: ApplicationFiled: October 26, 2009Publication date: September 15, 2011Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: George A. Beller, David K. Glover, Alexander L. Klibanov, Craig H. Meyer, Dayuan Li, Amit Patel, Christopher M. Kramer
-
Patent number: 7998462Abstract: An improved linker which lacks chiral centers between a hydrophobic anchor for coupling to lipid-based particles and a targeting agent has suitable hydrophobic/hydrophilic properties for use in vivo.Type: GrantFiled: October 16, 2007Date of Patent: August 16, 2011Assignee: Kereos, Inc.Inventor: William D. McGhee
-
Publication number: 20110190623Abstract: Disclosed are thermally-activatable liposomal compositions and methods for their use in the formulation and administration of therapeutic, prophylactic, and diagnostic agents. The disclosed liposome structures are capable of carrying a variety of biologically active reagents, and permitting their controlled release in vivo by exploiting properties of their thermoregulatable lability.Type: ApplicationFiled: August 5, 2009Publication date: August 4, 2011Applicant: The Methodist Hopsital Research InstituteInventors: King Chuen Li, Zheng Li, Guoting Qin
-
Patent number: 7976743Abstract: The present invention provides gas-containing liposomes. In particular, the present invention provide methods of generating gas-containing liposomes where the gas is introduced under pressure, as well as gas-containing liposomes which contain a large volume of gas (e.g., 10 ul of gas per 5 mg of gas-containing liposomes). In certain embodiments, the gas-containing liposomes contain nitric oxide gas. In some embodiments, such nitric oxide containing liposomes are used to treat a medical condition that is treatable by nitric oxide gas (e.g., intimal hyperplasia).Type: GrantFiled: October 16, 2007Date of Patent: July 12, 2011Assignees: Northwestern University, Board of Regents, The University of Texas SystemInventors: Shaoling Huang, Patrick Kee, Robert C. MacDonald, David McPherson
-
Publication number: 20110165069Abstract: The present invention relates to a method for preparing a radiolabeled macromolecule, the method comprising contacting a macromolecule with a carbon encapsulated nanoparticle composite having a radioactive particulate core in an aqueous medium comprising a pH selected to promote short-range attractive forces between the nanoparticles and the macromolecule by attenuating repulsive electrostatic forces.Type: ApplicationFiled: April 23, 2009Publication date: July 7, 2011Applicant: The Australian National UniversityInventors: Ross Wentworth Stephens, Timothy John Senden, David Wallace King
-
Publication number: 20110165070Abstract: The present invention relates to a method for preparing a radiolabeled synthetic polymer, the method comprising contacting a synthetic polymer with a carbon encapsulated nanoparticle composite having a radioactive particulate core in an aqueous medium comprising an electrolyte concentration or pH selected to promote short-range attractive forces between the nanoparticles and the synthetic polymer by attenuating long-range electrostatic repulsive forces.Type: ApplicationFiled: April 23, 2009Publication date: July 7, 2011Applicant: The Australian National UniversityInventors: Ross Wentworth Stephens, Timothy John Senden, David Wallace King
-
Publication number: 20110165067Abstract: Carbohydrate functionalized catanionic vesicles that include a glycoconjugate and/or peptidoconjugate for vaccination or drug delivery, methods for forming these, and methods of using these.Type: ApplicationFiled: August 18, 2008Publication date: July 7, 2011Applicant: University of Maryland Office of Technology CommercializationInventors: Douglas S. English, Philip R. DeShong, Daniel C. Stein, Sara Lioi, Ju-Hee Park, Emily J. Danoff, Glen B. Thomas
-
Publication number: 20110165068Abstract: This invention relates to a liposome medicament, and, more particularly, a liposome medicament with targeting function. The liposome medicament includes a medicament that is encapsulated in a liposome, and the medicament contains an effector molecule or an effector molecule that is combined with a first ligand, and a second ligand that is connected onto the surface of the liposome. The first ligand and/or the second ligand can specifically bind to target tissues or target cells to be treated. Preferably, the first ligand and/or the second ligands are antibodies, such as monoclonal antibodies. This invention also relates to a method of preparation of the liposome medicament and use of the medicament for treatment of diseases especially tumors. This invention further relates to a pharmaceutical composition of the liposome medicament and a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 2, 2010Publication date: July 7, 2011Inventors: Yanfang Liu, Jia Liu
-
Publication number: 20110158903Abstract: One pot process of preparing multifunctional liposome drug is provided. In this one pot process, liposome reacted with radionuclide labeled solution, chemotherapy drug, and targeted ligand at appropriate temperature. The product in this invention for preparation multifunctional liposome drugs in for imaging, delivery and targeting in cancer diagnosis and therapy has proved to be more simple, convenient, effective and easier than the prior art is.Type: ApplicationFiled: December 31, 2009Publication date: June 30, 2011Applicant: Institute of Nuclear Energy Research Atomic Energy Council, Executive YuanInventors: SHU-PEI CHIU, Te-Wei Lee, Chia-Yu Yu, Su-Jung Chen, Chung-Li Ho, Wei-Chuan Hsu, Ya-Jen Chang
-
Patent number: 7968129Abstract: The invention relates to a cosmetic preparation which includes a skin care complex having an anti-ageing effect. The complex consists of liposomes comprising a mixture of cosmetic oil, extract of Plukenetia volubilis seeds, extract of Cynara scolymus leaves and hydrogenated retinol. The liposomes are homogeneously dispersed in a gel network consisting of water and a gel-forming agent.Type: GrantFiled: June 28, 2007Date of Patent: June 28, 2011Assignee: Coty Prestige Lancaster Group GmbHInventors: Karin Golz-Berner, Leonhard Zastrow
-
Patent number: 7968306Abstract: Methods of measuring the SFA and sPLA2 activities in a mammalian subject are provided. The methods include: providing a substrate comprising a fluorescently labeled carboxylic acid and a negatively charged phospholipid in an organic solvent such as ethanol, mixing the substrate with phospholipase A2 and a biological sample from the subject, and detecting the fluorescence intensity change to determine the SFA and sPLA2 activity in the sample. A decrease in SFA activity in the test sample as compared to the SFA activity in the control sample indicates that the subject has developed or is about to develop inflammation. An increase in sPLA2 activity in the test sample as compared to the sPLA2 activity in the control sample indicates that the subject has developed or is about to develop inflammation. Further disclosed is a kit for practicing the above methods.Type: GrantFiled: December 12, 2008Date of Patent: June 28, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Francis H. C. Tsao, Keith C. Meyer
-
Publication number: 20110123601Abstract: The present invention provides a multilayer vehicle, including a mesoporous silica core and a lipid bilayer coating thereon. Hydrophobic molecules are formed between the silica core and lipid layer. Additionally, methods and uses of the multilayer vehicle are also provided.Type: ApplicationFiled: November 22, 2010Publication date: May 26, 2011Applicant: NATIONAL TSING HUA UNIVERSITYInventors: Ja-An HO, Li-Sheng Wang, Chia-Min Yang, Li-Chen Wu
-
Publication number: 20110104052Abstract: The present invention provides, in general, compositions comprising a hydrogel and an agent, for example a therapeutic agent or an imaging agent, for locoregional delivery. In certain preferred embodiments of the invention, the hydrogel compositions are detectable by Magnetic Responance and CT Scan and are used for locoregional delivery of therapeutic agents, for example chemotherapeutic agents. The invention also features polymer matrix compositions comprising nanoparticles that can be loaded after polymerization with bioactive agents, for example a diagnostic agent or therapeutic agent.Type: ApplicationFiled: December 3, 2008Publication date: May 5, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Bradley Powers Barnett, Jeffrey Geschwind
-
Publication number: 20110070153Abstract: The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.Type: ApplicationFiled: August 3, 2010Publication date: March 24, 2011Inventors: Roderick A. Hyde, Muriel Y. Ishikawa, Wayne R. Kindsvogel, Gary L. McKnight, Elizabeth A. Sweeney, Lowell L. Wood, JR.
-
Publication number: 20110070155Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compositions may be part of a kit for administering the anti-CD74 immunoconjugate compositions in therapeutic and/or diagnostic methods.Type: ApplicationFiled: September 27, 2010Publication date: March 24, 2011Applicant: IMMUNOMEDICS INC.Inventors: Gary L. Griffiths, Hans J. Hansen, David M. Goldenberg, Bo B. Lundberg
-
Publication number: 20110070154Abstract: The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.Type: ApplicationFiled: August 3, 2010Publication date: March 24, 2011Inventors: Roderick A. Hyde, Muriel Y. Ishikawa, Wayne R. Kindsvogel, Gary L. McKnight, Elizabeth A. Sweeney, Lowell L. Wood, JR.
-
Publication number: 20110027171Abstract: Using liposomes to deliver bioactive agents to cancer or tumor cells and compositions of specific lipids that form liposomes to deliver a biologically active agent.Type: ApplicationFiled: October 5, 2007Publication date: February 3, 2011Inventor: Sofou Stavroula
-
Patent number: 7875288Abstract: Provided is a method for treatment of blood coagulation disorders. The method comprises administering to an individual compositions comprising lipidic particles comprising phosphatidylcholine, phosphatidylinositol and cholesterol. One or more peptides, polypeptides or proteins involved in the blood coagulation cascade are associated with the lipidic particles.Type: GrantFiled: March 30, 2007Date of Patent: January 25, 2011Assignee: The Research Foundation of State University of New YorkInventors: Sathy V. Balu-Iyer, Robert M. Straubinger, Razvan Miclea, Aaron Peng
-
Patent number: 7875289Abstract: Provided are lipidic particles comprising phosphatidylcholine, phosphatidylinositol and cholesterol. Also provided are compositions comprising the lipidic particles and having associated therewith therapeutic agents such as peptides, polypeptides or proteins. In these compositions, the therapeutic agents have reduced immunogenicity and/or longer circulating time. These compositions can be used for therapeutic administration of the peptides, polypeptides and/or proteins.Type: GrantFiled: March 30, 2007Date of Patent: January 25, 2011Assignee: The Research Foundation of State University of New YorkInventors: Sathy V. Balu-Iyer, Robert M. Straubinger, Razvan Miclea, Aaron Peng
-
Publication number: 20110002844Abstract: Disclosed are stabilized polymersomes having layer structures. Such stabilized polymersomes are, in some embodiments, biocompatible, and are capable of enhanced, sustained release of agents. Also disclosed are related methods for synthesizing such stabilized polymersomes and methods for using such polymersomes for delivery of therapeutic, imaging, and various other agents.Type: ApplicationFiled: February 11, 2009Publication date: January 6, 2011Applicant: The Trustees of the University of PennsylvaniaInventors: Joshua S. Katz, Jason A. Burdick, Daniel A. Hammer
-
Patent number: 7829064Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates compositions in therapeutic and/or diagnostic methods.Type: GrantFiled: November 12, 2003Date of Patent: November 9, 2010Assignee: Immunomedics, Inc.Inventors: Gary L. Griffiths, Hans J. Hansen, David M. Goldenberg, Bo B. Lundberg
-
Publication number: 20100272636Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions.Type: ApplicationFiled: May 28, 2010Publication date: October 28, 2010Applicants: THE OHIO STATE UNIVERSITY, IMMUNOMEDICS, INC.Inventors: John C. Byrd, David M. Goldenberg, Hans J. Hansen
-
Publication number: 20100226853Abstract: Provided herein are [18F]-labeled compounds having a chemical structure: R1 is 18F, 1-piperazinyl-4-CH2CH2—18F or 1-piperazinyl-4-CH2CH2OCH2CH2—18F, R2 is CH3 or 18F and R3 is Cl or 18F, such that only one of R1, R2 and R3 comprise an 18F. Also provided are methods for in vivo imaging using the [18F]-labeled compounds, particularly methods of imaging utilizing positron emission tomography. These methods are effective for diagnosing a pathophysiological condition susceptible to treatment with kinase inhibitor(s) in a subject, or for determining whether a cancer in a subject that is susceptible to being treated with a kinase inhibitor has developed resistance or increased sensitivity to the same and for maximizing tumor response to akinase inhibitor with minimal toxicity to the subject.Type: ApplicationFiled: April 5, 2010Publication date: September 9, 2010Inventors: Darren R. Veach, Nagavara Kishore Pillarsetty, Steven M. Larson, Elmer B. Santos, Mohammad Namavari
-
Publication number: 20100196265Abstract: Anti-EGFR family member antibodies and bispecific antibodies comprising one or more anti-EGFR family member antibodies are disclosed. These antibodies can be used to advantage to specifically target forms of cancer associated with the overexpression of members of the EGFR protein family.Type: ApplicationFiled: November 20, 2007Publication date: August 5, 2010Inventors: Gregory P. Adams, Eva M. Horak, Louis M. Weiner, James D. Marks
-
Patent number: 7763264Abstract: A topical composition for controlling the metabolism and/or distribution of subcutaneous fat and/or moderating the appearance of cellulite, comprising, as an active ingredient, phosphatidylcholine together with a solvent operative to maintain the phosphatidylcholine in solution, and a buffer which maintains the composition in the range of pH 7.5-9.0. Typically, the composition includes less than 10% by weight water. The composition may include further active ingredients such as xanthines. Also disclosed are methods for using the composition.Type: GrantFiled: April 21, 2006Date of Patent: July 27, 2010Inventor: John Kulesza
-
Publication number: 20100178243Abstract: The present invention relates to a method of stabilizing a low molecular weight compound in a cationic liposome, wherein said compound has a low solubility in a lipid membrane and/or a low permeability across a lipid membrane. Preferrably, the compound is modified in order to increase lipid membrane solubility and/or lipid membrane permeability. After delivery of the cationic liposome to a target site, particularly a target site in an organism, the modification is reversed and the low molecular weight compound may enact its desired activity.Type: ApplicationFiled: December 22, 2009Publication date: July 15, 2010Applicant: MediGene AGInventors: Heinrich Haas, Thomas Fichert, Brita Schulze, Toralf Peymann, Uwe Michaelis, Michael Teifel
-
Patent number: 7749485Abstract: Composition for diagnostic or therapeutic use which comprises an assembly comprising an active agent. The assembly comprises a liposome and a plurality of micellar components associated thereto, said micellar components being associated to the outer surface of the envelope of said liposome through a substantially electrostatic interaction, When an active compound is incorporated into the micelles, a substantial amount of said active compound can be linked to a singe liposome. Furthermore, the presence of the outer micellar layer allows to increase the residence time of said liposome in the blood stream.Type: GrantFiled: May 31, 2005Date of Patent: July 6, 2010Assignee: Bracco Research S.A.Inventors: Herve Tournier, Roland Hyacinthe, Michel Schneider